Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT

Mitja Nabergoj*, Katya Mauff, Dietrich Beelen, Arnold Ganser, Nicolaus Kröger, Friedrich Stölzel, Jürgen Finke, Jakob Passweg, Jan Cornelissen, Natalie Schub, Joan Hendrik Veelken, Yves Beguin, Keith Wilson, Tsila Zuckerman, Mathilde Hunault-Berger, Bruno Lioure, Rocio Parody Porras, Pascal Turlure, Tessa Kerre, Linda KosterPatrick J. Hayden, Francesco Onida, Christof Scheid, Yves Chalandon, Marie Robin, Ibrahim Yakoub-Agha*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)
47 Downloads (Pure)

Abstract

We performed a registry study on therapy-related myeloid neoplasm (t-MN), both therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) following treatment for breast cancer who underwent a first allogeneic hematopoietic cell transplant (allo-HCT). Of 252 identified female patients (median age 57 years), 77% were transplanted for t-AML and 23% for t-MDS, with a median time from breast cancer diagnosis to the diagnosis of tMN and subsequent allo-HCT of 3.7 and 4.6 years, respectively. At transplant, 191 patients were in remission for breast cancer, while 4 were not (57 missing). T-MN was in a complete remission at the time of transplant in 67% of patients. 2-year overall survival, relapse free-survival, relapse incidence and non-relapse mortality were 50%, 45%, 33%, and 22%, respectively. Multivariable analysis revealed that if the t-MN was not in CR pre-transplant, this was associated with lower OS, RFS, and a higher relapse incidence. Seventeen cases of breast cancer recurrence were recorded after a median of 2.4 years post-transplant, and relapse of primary breast cancer accounted for 7% of deaths. This study indicates that allo-HCT for t-MN following treatment for breast cancer shows encouraging transplant outcomes. The incidence of breast cancer relapse post-transplant remains a cause for concern.

Original languageEnglish
Pages (from-to)1072-1078
Number of pages7
JournalBone Marrow Transplantation
Volume57
Issue number7
Early online date22 Apr 2022
DOIs
Publication statusPublished - Jul 2022

Bibliographical note

Funding Information:
Funding for this study was indirectly provided by support of the CMWP of the EBMT.

Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature Limited.

Fingerprint

Dive into the research topics of 'Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT'. Together they form a unique fingerprint.

Cite this